Candidiasis and the impact of flow cytometry on antifungal drug discovery

References

• McCarty TP, Pappas PG. Invasive candidiasis. Infect Dis Clin North Am. 2016;30:103–124.
   PubMed Web of Science ®Google Scholar
• Edmond MB, Wallace SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis Off Publ. 1999;29:239–244.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39:309–317.
   PubMed Web of Science ®Google Scholar
• Magill SS, Edwards JR, Bamberg W, et al. Multistate point-prevalence survey of health care–associated infections. N Engl J Med. 2014;370:1198–1208.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Kullberg BJ, Bow EJ, et al. Early treatment of candidemia in adults: a review. Med Mycol. 2011;49:113–120.
   PubMed Web of Science ®Google Scholar
• Strollo S. Epidemiology of hospitalizations associated with invasive candidiasis, United States, 2002–2012. Emerg Infect Dis. 2016;23(1):7–13.
   PubMed Web of Science ®Google Scholar
• Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis Off Publ. 2005;41:1232–1239.
   PubMed Web of Science ®Google Scholar
• Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001-2010. Emerg Infect Dis. 2014;20:1149–1155.
   PubMed Web of Science ®Google Scholar
• Chen S, Slavin M, Nguyen Q, et al. Active surveillance for candidemia, Australia. Emerg Infect Dis. 2006;12:1508–1516.
   PubMed Web of Science ®Google Scholar
• Li F, Wu L, Cao B, et al. Surveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011. BMC Infect Dis. 2013;13:353.
   PubMed Web of Science ®Google Scholar
• Li Y, Du M, Chen L-A, et al. Nosocomial bloodstream infection due to Candida spp. in China: species distribution, clinical features, and outcomes. Mycopathologia. 2016;181:485–495.
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Tascini C, et al. Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. Eur J Intern Med. 2017;41:33–38.
   PubMed Web of Science ®Google Scholar
• Tukenmez Tigen E, Bilgin H, Perk Gurun H, et al. Risk factors, characteristics, and outcomes of candidemia in an adult intensive care unit in Turkey. Am J Infect Control. 2017;45:e61–e63.
   PubMed Web of Science ®Google Scholar
• Wu Z, Liu Y, Feng X, et al. Candidemia: incidence rates, type of species, and risk factors at a tertiary care academic hospital in China. Int J Infect Dis. 2014;22:4–8.
   PubMed Web of Science ®Google Scholar
• Mermutluoglu C, Deveci O, Dayan S, et al. Antifungal susceptibility and risk factors in patients with candidemia. Kandidemili Haslarda Risk Faktörleri Ve Antifung. Duyarlılık. 2016;48:199–203.
   Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. The epidemiology and outcomes of invasive Candida infections among organ transplant recipients in the United States: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl Infect Dis Off J Transpl Soc. 2016;18:921–931.
   PubMed Web of Science ®Google Scholar
• Eliakim-Raz N, Babaoff R, Yahav D, et al. Epidemiology, microbiology, clinical characteristics, and outcomes of candidemia in internal medicine wards-a retrospective study. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2016;52:49–54.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Moet GJ, Messer SA, et al. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob Agents Chemother. 2011;55:561–566.
   PubMed Web of Science ®Google Scholar
• Zhou Z-L, Lin -C-C, Chu W-L, et al. The distribution and drug susceptibilities of clinical Candida species in TSARY 2014. Diagn Microbiol Infect Dis. 2016;86:399–404.
   PubMed Web of Science ®Google Scholar
• Yang Z-T, Wu L, Liu X-Y, et al. Epidemiology, species distribution and outcome of nosocomial Candida spp. bloodstream infection in Shanghai. BMC Infect Dis. 2014;14:241.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Taramasso L, Nicco E, et al. Epidemiology, species distribution, antifungal susceptibility and outcome of nosocomial candidemia in a tertiary care hospital in Italy. PloS One. 2011;6:e24198.
   PubMed Web of Science ®Google Scholar
• Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PloS One. 2015;10:e0120452.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2010;14:e954–966.
   PubMed Web of Science ®Google Scholar
• Adhikary R, Joshi S. Species distribution and anti-fungal susceptibility of Candidaemia at a multi super-specialty center in Southern India. Indian J Med Microbiol. 2011;29:309–311.
   PubMed Web of Science ®Google Scholar
• Chander J, Singla N, Sidhu SK, et al. Epidemiology of Candida blood stream infections: experience of a tertiary care centre in North India. J Infect Dev Ctries. 2013;7:670–675.
   PubMed Web of Science ®Google Scholar
• Hii I-M, Chang H-L, Lin L-C, et al. Changing epidemiology of candidemia in a medical center in middle Taiwan. J Microbiol Immunol Infect. 2015;48:306–315.
   PubMedGoogle Scholar
• Montagna MT, Lovero G, Borghi E, et al. Candidemia in intensive care unit: a nationwide prospective observational survey (GISIA-3 study) and review of the European literature from 2000 through 2013. Eur Rev Med Pharmacol Sci. 2014;18:661–674.
   PubMed Web of Science ®Google Scholar
• Al-Rawahi GN, Roscoe DL. Ten-year review of candidemia in a Canadian tertiary care centre: predominance of non-albicans Candida species. Can J Infect Dis Med Microbiol. 2013;24:e65.
   PubMed Web of Science ®Google Scholar
• Satoh K, Makimura K, Hasumi Y, et al. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41–44.
   PubMed Web of Science ®Google Scholar
• Borman AM, Szekely A, Johnson EM. Isolates of the emerging pathogen Candida auris present in the UK have several geographic origins. Med Mycol. 2017;55:563–567. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Kumar VA, Sharma C, et al. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis. 2014;33:919–926.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. Emergence of Candida auris: an international call to arms. Clin Infect Dis. 2017;64:141–143.
   PubMed Web of Science ®Google Scholar
• Emara M, Ahmad S, Khan Z, et al. Candida auris Candidemia in Kuwait, 2014. Emerg Infect Dis. 2015;21:1091.
   PubMed Web of Science ®Google Scholar
• Kumar D, Banerjee T, Pratap CB, et al. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. J Infect Dev Ctries. 2015;9:435–437.
   PubMed Web of Science ®Google Scholar
• Lee WG, Shin JH, Uh Y, et al. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol. 2011;49:3139–3142.
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134–140.
   PubMed Web of Science ®Google Scholar
• Magobo RE, Corcoran C, Seetharam S, et al. Candida auris–associated candidemia, South Africa. Emerg Infect Dis. 2014;20:1250.
   PubMed Web of Science ®Google Scholar
• McCarthy M. Hospital transmitted Candida auris infections confirmed in the US. BMJ. 2016;355:i5978.
   PubMed Web of Science ®Google Scholar
• Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis. 2017;23:162.
   PubMed Web of Science ®Google Scholar
• Ruiz Gaitán AC, Moret A, López Hontangas JL, et al. Nosocomial fungemia by Candida auris: first four reported cases in continental Europe. Rev Iberoam Micol. 2017;34:23–27.
   PubMed Web of Science ®Google Scholar
• Sarma S, Kumar N, Sharma S, et al. Candidemia caused by amphotericin B and Fluconazole resistant Candida auris. Indian J Med Microbiol. 2013;31:90.
   PubMed Web of Science ®Google Scholar
• Schelenz S, Hagen F, Rhodes JL, et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control. 2016;5:35.
   PubMed Web of Science ®Google Scholar
• Vallabhaneni S, Kallen A, Tsay S, et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. Am J Transplant. 2017;17:296–299.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Alampalli SV, Nageshan RK, et al. Draft genome of a commonly misdiagnosed multidrug resistant pathogen Candida auris. BMC Genomics. 2015;16:686.
   PubMed Web of Science ®Google Scholar
• Mizusawa M, Miller H, Green R, et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories? J Clin Microbiol. 2017;55:638–640.
   PubMed Web of Science ®Google Scholar
• Wattal C, Oberoi JK, Goel N, et al. Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) for rapid identification of micro-organisms in the routine clinical microbiology laboratory. Eur J Clin Microbiol Infect Dis. 2017;36:807–812.
   PubMed Web of Science ®Google Scholar
• Kumar A, Sachu A, Mohan K, et al. Simple low cost differentiation of Candida auris from Candida haemulonii complex using CHROMagar Candida medium supplemented with Pal’s medium. Rev Iberoam Micol. 2017;34:109–111.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1–e50.
   PubMed Web of Science ®Google Scholar
• Campoy S, Adrio JL. Antifungals. Biochem Pharmacol. 2017;133:86–96.
   PubMed Web of Science ®Google Scholar
• Lemke A, Kiderlen AF, Kayser O. Amphotericin B. Appl Microbiol Biotechnol. 2005;68:151–162.
   PubMed Web of Science ®Google Scholar
• Gray KC, Palacios DS, Dailey I, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci. 2012;109:2234–2239.
   PubMed Web of Science ®Google Scholar
• Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73:919–934.
   PubMed Web of Science ®Google Scholar
• Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32:686–693.
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58:2–13.
   PubMed Web of Science ®Google Scholar
• Kołaczkowska A, Kołaczkowski M. Drug resistance mechanisms and their regulation in non-albicans Candida species. J Antimicrob Chemother. 2016;71:1438–1450.
   PubMed Web of Science ®Google Scholar
• Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008;46:120–128.
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C. Triazole antifungal agents in invasive fungal infections. Drugs. 2011;71:2405–2419.
   PubMed Web of Science ®Google Scholar
• Brüggemann RJM, Alffenaar J-WC, Blijlevens NMA, et al. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis. 2009;48:1441–1458.
   PubMed Web of Science ®Google Scholar
• Chen SC-A, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections. Drugs. 2011;71:11–41.
   PubMed Web of Science ®Google Scholar
• Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009;43:1647–1657.
   PubMed Web of Science ®Google Scholar
• Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal infections. Int J Microbiol. 2011;2012:e713687.
   PubMedGoogle Scholar
• Vermes A, Guchelaar HJ, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother. 2000;46:171–179.
   PubMed Web of Science ®Google Scholar
• Whaley SG, Berkow EL, Rybak JM, et al. Azole antifungal resistance in candida albicans and emerging non-albicans Candida species. Front Microbiol [Internet]. 2017;7. cited 2017 May 17. Available from: http://journal.frontiersin.org/article/10.3389/fmicb.2016.02173/full
   PubMed Web of Science ®Google Scholar
• Sanglard D, Ischer F, Bille J. Role of ATP-binding-cassette transporter genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother. 2001;45:1174–1183.
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Fiori B, et al. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob Agents Chemother. 2005;49:668.
   PubMed Web of Science ®Google Scholar
• Coste AT, Karababa M, Ischer F, et al. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot Cell. 2004;3:1639–1652.
   PubMed Web of Science ®Google Scholar
• Holmes AR, Lin Y-H, Niimi K, et al. ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant candida albicans clinical isolates. Antimicrob Agents Chemother. 2008;52:3851–3862.
   PubMed Web of Science ®Google Scholar
• Tsao S, Rahkhoodaee F, Raymond M. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob Agents Chemother. 2009;53:1344–1352.
   PubMed Web of Science ®Google Scholar
• Borecká S, Pinjon E, Sullivan DJ, et al. Cdr2p contributes to fluconazole resistance in clinical isolates. Can J Microbiol. 2011;57:416–426.
   PubMed Web of Science ®Google Scholar
• Barker KS, Pearson MM, Rogers PD. Identification of genes differentially expressed in association with reduced azole susceptibility in Saccharomyces cerevisiae. J Antimicrob Chemother. 2003;51:1131–1140.
   PubMed Web of Science ®Google Scholar
• Alarco A-M, Raymond M. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J Bacteriol. 1999;181:700–708.
   PubMed Web of Science ®Google Scholar
• MacPherson S, Akache B, Weber S, et al. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob Agents Chemother. 2005;49:1745.
   PubMed Web of Science ®Google Scholar
• Löffler J, Kelly SL, Hebart H, et al. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains. FEMS Microbiol Lett. 1997;151:263–268.
   PubMed Web of Science ®Google Scholar
• Orozco AS, Higginbotham LM, Hitchcock CA, et al. Mechanism of fluconazole resistance in Candida krusei. Antimicrob Agents Chemother. 1998;42:2645.
   PubMed Web of Science ®Google Scholar
• Xu Y, Sheng F, Zhao J, et al. ERG11 mutations and expression of resistance genes in fluconazole-resistant Candida albicans isolates. Arch Microbiol. 2015;197:1087–1093.
   PubMed Web of Science ®Google Scholar
• Lopez-Ribot JL, McAtee RK, Lee LN, et al. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal Candidiasis. Antimicrob Agents Chemother. 1998;42:2932.
   PubMed Web of Science ®Google Scholar
• Kelly SL, Lamb DC, Kelly DE, et al. Resistance to fluconazole and amphotericin in Candida albicans from AIDS patients. Lancet. 1996;348:1523–1524.
   PubMed Web of Science ®Google Scholar
• Martel CM, Parker JE, Bader O, et al. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob Agents Chemother. 2010;54:4527–4533.
   PubMed Web of Science ®Google Scholar
• Nolte FS, Parkinson T, Falconer DJ, et al. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother. 1997;41:196.
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Lee S, Park S, et al. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-β-d-glucan synthase: implication for the existing susceptibility breakpoint. Antimicrob Agents Chemother. 2009;53:3690–3699.
   PubMed Web of Science ®Google Scholar
• Park S, Kelly R, Kahn JN, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical candida sp. Isolates. Antimicrob Agents Chemother. 2005;49:3264.
   PubMed Web of Science ®Google Scholar
• Walker LA, Munro CA, Bruijn ID, et al. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLOS Pathog. 2008;4:e1000040.
   PubMed Web of Science ®Google Scholar
• Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother. 2004;48:3407–3411.
   PubMed Web of Science ®Google Scholar
• Stevens DA, Ichinomiya M, Koshi Y, et al. Escape of Candida from caspofungin inhibition at concentrations above the MIC (Paradoxical Effect) accomplished by increased cell wall chitin; evidence for β-1,6-glucan synthesis inhibition by caspofungin. Antimicrob Agents Chemother. 2006;50:3160.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, et al. Assessment of the paradoxical effect of caspofungin in therapy of Candidiasis. Antimicrob Agents Chemother. 2006;50:1293–1297.
   PubMed Web of Science ®Google Scholar
• Dick JD, Merz WG, Saral R. Incidence of polyene-resistant yeasts recovered from clinical specimens. Antimicrob Agents Chemother. 1980;18:158–163.
   PubMed Web of Science ®Google Scholar
• Sokol-Anderson ML, Brajtburg J, Medoff G. Amphotericin B-induced oxidative damage and killing of “Candida albicans.”. J Infect Dis. 1986;154:76–83.
   PubMed Web of Science ®Google Scholar
• Hope WW, Tabernero L, Denning DW, et al. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob Agents Chemother. 2004;48:4377–4386.
   PubMed Web of Science ®Google Scholar
• Dodgson AR, Dodgson KJ, Pujol C, et al. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob Agents Chemother. 2004;48:2223–2227.
   PubMed Web of Science ®Google Scholar
• Vandeputte P, Pineau L, Larcher G, et al. Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata. Mycopathologia. 2011;171:11–21.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Woosley LN, et al. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol. 2013;51:2571–2581.
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Rex JH, Pappas PG, et al. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother. 2003;47:3149–3154.
   PubMed Web of Science ®Google Scholar
• Law D, Moore CB, Wardle HM, et al. High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother. 1994;34:659–668.
   PubMed Web of Science ®Google Scholar
• Prigent G, Aït-Ammar N, Levesque E, et al. Echinocandin resistance in Candida species isolates from liver transplant recipients. Antimicrob Agents Chemother. 2017;61:e01229–16.
   PubMed Web of Science ®Google Scholar
• Wiederhold NP. Echinocandin resistance in Candida species: a review of recent developments. Curr Infect Dis Rep. 2016;18:42.
   PubMed Web of Science ®Google Scholar
• Imtiaz T, Lee KK, Munro CA, et al. Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a Candida albicans bloodstream isolate following brief exposure to caspofungin. J Med Microbiol. 2012;61:1330–1334.
   PubMed Web of Science ®Google Scholar
• Fothergill AW, Sutton DA, McCarthy DI, et al. Impact of new antifungal breakpoints on antifungal resistance in Candida species. J Clin Microbiol. 2014;52:994–997.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Moet GJ, Messer SA, et al. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY antimicrobial surveillance program (2008 to 2009). J Clin Microbiol. 2011;49:396–399.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Press EG, et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive Candidiasis due to Candida glabrata. Antimicrob Agents Chemother. 2012;56:4862.
   PubMed Web of Science ®Google Scholar
• Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56:1724–1732.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Clancy CJ. Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis. 2015;28:514.
   PubMed Web of Science ®Google Scholar
• Yoon SA, Vazquez JA, Steffan PE, et al. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob Agents Chemother. 1999;43:836.
   PubMed Web of Science ®Google Scholar
• Garcia-Effron G, Katiyar SK, Park S, et al. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob Agents Chemother. 2008;52:2305–2312.
   PubMed Web of Science ®Google Scholar
• Walker LA, Gow NAR, Munro CA. Elevated chitin content reduces the susceptibility of Candida species to caspofungin. Antimicrob Agents Chemother. 2013;57:146–154.
   PubMed Web of Science ®Google Scholar
• Ben-Ami R, Berman J, Novikov A, et al. Multidrug-resistant Candida haemulonii and C. auris. Tel Aviv Israel Emerg Infect Dis. 2017;23:195.
   PubMed Web of Science ®Google Scholar
• Chandra J, Mukherjee PK. Candida biofilms: development, architecture, and resistance. Microbiol Spectr [Internet]. 2015;3:4.
   Web of Science ®Google Scholar
• Tsui C, Kong EF, Jabra-Rizk MA. Pathogenesis of Candida albicans biofilm. Pathog Dis [Internet]. 2016;74(4):ftw018.
   PubMed Web of Science ®Google Scholar
• Sherry L, Ramage G, Kean R, et al. Biofilm-forming capability of highly virulent, multidrug-resistant Candida auris. Emerg Infect Dis. 2017;23:328–331.
   PubMed Web of Science ®Google Scholar
• Mathé L, Dijck PV. Recent insights into Candida albicans biofilm resistance mechanisms. Curr Genet. 2013;59:251–264.
   PubMed Web of Science ®Google Scholar
• Nett J, Lincoln L, Marchillo K, et al. Putative role of β-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother. 2007;51:510–520.
   PubMed Web of Science ®Google Scholar
• Nett JE, Crawford K, Marchillo K, et al. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother. 2010;54:3505–3508.
   PubMed Web of Science ®Google Scholar
• Taff HT, Mitchell KF, Edward JA, et al. Mechanisms of Candida biofilm drug resistance. Future Microbiol. 2003;8(10):1325–1337.
   Web of Science ®Google Scholar
• Nierode G, Kwon P, Dordick J, et al. Cell-based assay design for high-content screening of drug candidates. J Microbiol Biotechnol. 2016;26:213–225.
   PubMed Web of Science ®Google Scholar
• Edwards BS, Kuckuck FW, Prossnitz ER, et al. HTPS flow cytometry: a novel platform for automated high throughput drug discovery and characterization. J Biomol Screen. 2001;6:83–90.
   PubMed Web of Science ®Google Scholar
• Black CB, Duensing TD, Trinkle LS, et al. Cell-based screening using high-throughput flow cytometry. Assay Drug Dev Technol. 2011;9:13–20.
   PubMed Web of Science ®Google Scholar
• Simm C, Luan C-H, Weiss E, et al. High-throughput screen for identifying small molecules that target fungal zinc homeostasis. PLoS One. 2011;6:e25136.
   PubMed Web of Science ®Google Scholar
• Holmes AR, Keniya MV, Ivnitski-Steele I, et al. The monoamine oxidase a inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. Antimicrob Agents Chemother. 2012;56:1508–1515.
   PubMed Web of Science ®Google Scholar
• Chan C-Y, Prudom C, Raines SM, et al. Inhibitors of V-ATPase proton transport reveal uncoupling functions of tether linking cytosolic and membrane domains of V0 Subunit a (Vph1p). J Biol Chem. 2012;287:10236–10250.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zeng H, Tian J, et al. Antifungal mechanism of essential oil from Anethum graveolens seeds against Candida albicans. J Med Microbiol. 2013;62:1175–1183.
   PubMed Web of Science ®Google Scholar
• Bernardo SM, Allen CP, Waller A, et al. An automated high-throughput cell-based multiplexed flow cytometry assay to identify novel compounds to target Candida albicans virulence-related proteins. PLoS One. 2014;9:e110354.
   PubMed Web of Science ®Google Scholar
• Wang K, Yan J, Dang W, et al. Dual antifungal properties of cationic antimicrobial peptides polybia-MPI: membrane integrity disruption and inhibition of biofilm formation. Peptides. 2014;56:22–29.
   PubMed Web of Science ®Google Scholar
• García-Varela R, García-García RM, Barba-Dávila BA, et al. Antimicrobial activity of rhoeo discolor phenolic rich extracts determined by flow cytometry. Molecules. 2015;20:18685–18703.
   PubMed Web of Science ®Google Scholar
• Ding Y, Li Y, Li Z, et al. Alteramide B is a microtubule antagonist of inhibiting Candida albicans. Biochim Biophys Acta BBA Gen Subj. 2016;1860:2097–2106.
   PubMed Web of Science ®Google Scholar
• Jia W, Zhang H, Li C, et al. The calcineruin inhibitor cyclosporine a synergistically enhances the susceptibility of Candida albicans biofilms to fluconazole by multiple mechanisms. BMC Microbiol. 2016;16:113.
   PubMed Web of Science ®Google Scholar
• Yun J, Lee DG. Role of potassium channels in chlorogenic acid-induced apoptotic volume decrease and cell cycle arrest in Candida albicans. Biochim Biophys Acta BBA Gen Subj. 2017;1861:585–592.
   PubMed Web of Science ®Google Scholar
• Costa Silva RA, Da Silva CR, de Andrade Neto JB, et al. In vitro anti-Candida activity of selective serotonin reuptake inhibitors against fluconazole-resistant strains and their activity against biofilm-forming isolates. Microb Pathog. 2017;107:341–348.
   PubMed Web of Science ®Google Scholar
• Millard PJ, Roth BL, Thi HP, et al. Development of the FUN-1 family of fluorescent probes for vacuole labeling and viability testing of yeasts. Appl Environ Microbiol. 1997;63:2897–2905.
   PubMed Web of Science ®Google Scholar
• Pina-Vaz C, Costa-de-Oliveira S, Rodrigues AG, et al. Comparison of two probes for testing susceptibilities of pathogenic yeasts to voriconazole, itraconazole, and caspofungin by flow cytometry. J Clin Microbiol. 2005;43:4674–4679.
   PubMed Web of Science ®Google Scholar
• Gilbert DF, Wilson JC, Nink V, et al. Multiplexed labeling of viable cells for high-throughput analysis of glycine receptor function using flow cytometry. Cytometry A. 2009;75A:440–449.
   Web of Science ®Google Scholar
• Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods. 2006;3:361–368.
   PubMed Web of Science ®Google Scholar
• Miranda CG, Solana ME, Curto MDLA, et al. A flow cytometer-based method to simultaneously assess activity and selectivity of compounds against the intracellular forms of Trypanosoma cruzi. Acta Trop. 2015;152:8–16.
   PubMed Web of Science ®Google Scholar
• Spurgeon BEJ, Aburima A, Oberprieler NG, et al. Multiplexed phosphospecific flow cytometry enables large-scale signaling profiling and drug screening in blood platelets. J Thromb Haemost. 2014;12:1733–1743.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Gentry T, Sebti S, et al. Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening. J Immunol Methods. 2004;292:59–71.
   PubMed Web of Science ®Google Scholar
• Robey RW, Lin B, Qiu J, et al. Rapid detection of ABC transporter interaction: potential utility in pharmacology. J Pharmacol Toxicol Methods. 2011;63:217–222.
   PubMed Web of Science ®Google Scholar
• Smith RA, Giorgio TD. Cell-based screening: a high throughput flow cytometry platform for identification of cell-specific targeting molecules. Comb Chem High Throughput Screen. 2004;7:141–151.
   PubMed Web of Science ®Google Scholar
• Feng Y, Mitchison TJ, Bender A, et al. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov. 2009;8:567–578.
   PubMed Web of Science ®Google Scholar
• Hernández P, Gorrochategui J, Primo D, et al. Drug discovery testing compounds in patients samples by automated flow cytometry. SLAS Technol. 2017 Jun;22(3):325–337.
   PubMed Web of Science ®Google Scholar
• Munguia J, Nizet V. Pharmacological targeting of the host–pathogen interaction: alternatives to classical antibiotics to combat drug-resistant superbugs. Trends Pharmacol Sci. 2017;38:473–488.
   PubMed Web of Science ®Google Scholar
• Allen RC, Popat R, Diggle SP, et al. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol. 2014;12:300–308.
   PubMed Web of Science ®Google Scholar
• Poltermann S, Nguyen M, Günther J, et al. The putative vacuolar ATPase subunit Vma7p of Candida albicans is involved in vacuole acidification, hyphal development and virulence. Microbiology. 2005;151:1645–1655.
   PubMed Web of Science ®Google Scholar
• Hilty J, Smulian AG, Newman SL. The Histoplasma capsulatum vacuolar ATPase is required for iron homeostasis, intracellular replication in macrophages and virulence in a murine model of histoplasmosis. Mol Microbiol. 2008;70:127–139.
   PubMed Web of Science ®Google Scholar
• Erickson T, Liu L, Gueyikian A, et al. Multiple virulence factors of Cryptococcus neoformans are dependent on VPH1. Mol Microbiol. 2001;42:1121–1131.
   PubMed Web of Science ®Google Scholar